Piatkova Irina
160

д.м.н., Блэктаунская молекулярная научно-исследовательская лаборатория, Западный Сидней, Новый Южный Уэльс, Австралия

PhD, UWS Blacktown Molecular Research Laboratory, Western Sydney Local Health District, NSW, Australia

E-mail: Этот адрес электронной почты защищен от спам-ботов. У вас должен быть включен JavaScript для просмотра.

Этот адрес электронной почты защищен от спам-ботов. У вас должен быть включен JavaScript для просмотра.

Этот адрес электронной почты защищен от спам-ботов. У вас должен быть включен JavaScript для просмотра.

Work: (02) 9851 6123

Mobile: 0431 858 212

Member

  • Member of the Australasian Association of Clinical Biochemists Steering Committee, Global Translational Medicine Consortium, EUSTM
  • Member of the Science Advisory Board (Biotechnology), USA
  • Associate Editor, Journal of Molecular Biology Research, Canada
  • Member of National Association of Testing Authorities, Australia (NATA)
  • University of Western Sydney Adjunct Fellow
  • Member of UWS Molecular Medicine Research Group

SUMMARY

  • PhD in science
  • more than twenty five years’ experience in diagnostic, teaching and research areas
  • experience in organisation and management of a laboratory
  • experience in the organisation of research projects
  • experience in staff training, manual preparation and liaising with customers, suppliers’ companies and contractors
  • teaching and supervision of postgraduate and undergraduate students
  • publications and reviews in peer-reviewed scientific journals
  • conference and workshop presentations

EDUCATION

  • PhD in Science, USSR. Completed in 1986
  • Recognised by Australian NOOSR and University of Toronto, Canada
  • Bachelor of Science with Distinction, Chemistry and Biology. (Recognised as a Master Degree by University of Toronto), Tashkent State University, USSR, 1975-1980
    Recognised by Australian NOOSR and University of Toronto, Canada

Continuing education (main)

  • HETI/UNE Diploma of Management. Current enrolment.
  • WSLHD Research Governance. WSLHD, March 2015
  • Good Clinical Practice for Principle Investigator. WSLHD, October 2013
  • Certificate IV in Frontline Management. WSLHD, September 2013
  • The Financial Management Education Program. HETI , May 2013
  • Risk Awareness Course for WSLHD Managers. April 2013
  • Laboratory Assessor/ Lead Assessor. NATA, May 2011
  • NATA Laboratory Audit. NATA, March 2010
  • Bioinformatics, Biotech Leaning Institute, USA, 2005-2006, E-course

EMPLOYMENT HISTORY

- Senior Hospital Scientist In Charge of Laboratory
UWS Blacktown Molecular Research Laboratory (former Diversity Health Institute Research Laboratory),
Western Sydney Local Health District, NSW, Australia
June 2005 – Current
- Hospital Scientist
ICPMR, Westmead Hospital, Westmead, NSW, Australia
Oct 1997 – June 2005
- Research Associate
(Leave without pay during my employment at Westmead Hospital)
Mount Sinai Hospital, Toronto, Canada
December 2001- March 2002
- Research Officer
Department of Medicine
North Shore Royal Hospital, Sydney, NSW, Australia
Feb 1996 – Oct 1997
- Scientific Officer
Department of Biological Sciences, Biotechnology,
Macquarie University, Sydney, NSW, Australia
Jan 1994 – Dec 1994
- Lecturer in Biochemistry
Tashkent Pharmaceutical Institute, Tashkent, USSR
1988-1992
- Research Officer
Academy of Science, USSR. (PhD scholarship is completed during this time).
1981-1987

LIST OF PUBLICATIONS (MAIN)


FIRST AUTHOR

  1. Chapter: Role of cytochrome p450 enzymes in psychotropic drug metabolism and clinical implications. In book: Cytochrome P450 Enzymes: Biochemistry, Pharmacology and Health Implications. NOVA USA. 2014.
  2. Chapter: Drug-Food Interaction. In book: Introduction to Functional Food Science: Textbook. Volume 1, Danik M Martirosyan, UTSW Medical Centerat Dallas, TX, USA, 2013.
  3. Chapter: Drug Interactions, Pharmacogenomics and Cardiovascular Complication; In book: Drug Discovery. InTech.2013 doi: 10.5772/48423, chapter 3, p 75-105.
  4. Cases of Adverse Reaction to Psychotropic Drugs and Possible Association with Pharmacogenetics. J. Pers. Med. 2012, 2(4), 149-157; doi:10.3390/jpm204014
  5. Pharmacogenetics and gender association with psychotic episodes on Nortriptyline lower doses. Patient cases. ISRN Pharmaceuticals, ISRN Pharmaceutics, vol. 2011, Article ID 805983, 2011. doi:10.5402/2011/805983.
  6. Suicide cases and Venlafaxine. ACTA Neuropsychiatrica 2011, DOI: 10.1111/j.1601-5215.2011.00566.x V 23, Issue 4, 156-160, 2011.
  7. Metabolism, menstruation and medication. Psychotropic drugs prescription for women. Synergy, Multicultural Mental Health Australia, Edition 1, 2011.
  8. Nutrigenomics and Metabolic Diseases. e-Diversity Journal, (3), December, 2010
  9. Warfarin Toxicity and Individual Variability—Clinical Case. Toxins. 2010; 2(11):2584-2592.
  10. Cytochrome P450 loss-of-function polymorphism genotyping on the Agilent Bioanalyzer and clinical application. Pharmacogenomics. Dec 2009, Vol 10, No 12
  11. Drug Hypersensitivity. Book Review. Australian Journal of Medical Science, Vol. 29, No. 4, Nov 2008: 151-152.
  12. Individualized Therapy for Diverse Australian Population. Santorini papers. Clinical Chemistry and Laboratory Medicine, Vol.44 No8, 2006.
  13. Efficient screening method for at-risk patients on the thiopurine therapy. Australian Journal of Medical Science. Vol.27, No.3, August 2006.
  14. HPLC method of Arecoline determination in human saliva. International J.Chromatography A., V 1032, III, p 93-95, April 2004.
  15. Quantitative analysis of gene expression by ion-pair high-performance liquid chromatography during Vitamin D supplementation. International Conference HPLC2003 papers, 2003.
  16. The biochemical nature of the cell envelope of a high cellulase-secreting mutant differs from that of the Trichoderma reesei wild type. Journal of Biotechnology 42, 53-59, 1995.
  17. Metanephrine and Normetanephrine Determination in urine and blood plasma by HPLC method. Clinical Chemistry, 5, 1989.(in Russian)
  18. Content of biologically active substances in aboveground parts of Hypericum. Plant Resources, Leningrad 4 1988.(in Russian)

COAUTHOR

  1. Clazapine-induced acute renal failure and Cytochrome P450 genotype. Australian and New Zealand Journal of Psychiatry,1–1, The Royal Australian and New Zealand College of Psychiatrists 2015
  2. Oxidative DNA Damage Levels in IBD patients Undergoing Infliximab Therapy. Gastroenterology 2011, Vol 140, Issue5, Supplement 1, Pages: S-278.
  3. CYP2D6 Genotyping by Liquid Chromatography-Electrospray Ionization Mass Spectrometry. Anal Bioanal Chem Jun 12, 2011.
  4. Normal thiopurine methyltransferase phenotype testing in a crohn disease patient with azathioprine induced myelosuppression. Internal Med J 2009; 39: 121-6.

REVIEWED ARTICLES IN

  • Pharmacogenomics, Future Medicine Journals, London, UK.
  • Journal of Molecular Biology Research, Canadian Centre of Science and Education, Canada.
  • Pharmacology, Biochemistry and Behaviour, Elsevier, International Journal.

CONFERENCE PRESENTATIONS

  • Serotonin toxicity and Cytochrome P450 genetic polymorphisms. The International Association of Forensic Toxicologists, 53d Meeting, Rome 2015.
  • International Congress on Personalised Medicine, Oral presentation, UPCP 2012, Italy, February 2012.
  • Can Cytochrome P450 polymorphisms be used as biomarkers for the serotonin syndrome and suicidal ideations? Oral Presentation. AACB Annual Scientific Conference, Sydney, October, 2011.
  • Bioinformatics Application in Clinical Laboratories. Oral Presentation. AACB annual scientific meeting, February 2011.
    • Cytochrome P450 loss-of-function polymorphisms should be included in patient record warning labels. Oral presentation. Australian Mutation Detection Meeting, Tasmania, 3-6 August 2010.
  • Cytochtome P450 genotyping in the interpretation of Forensic Toxicological results. Oral Presentation. Mutation Detection 10th International symposium on mutations in the Genome, Cyprus, 28 May - 1 June 2009.
  • CYP Poor Metaboliser Genotyping on the Agilent Bioanalyzer and Clinical Application. Oral Presentation. Molecular Diagnostics Europe Conference, Stockholm, Sweden, 19 and 20 May 2009.
  • Cytochrome P450 genotyping in interpretation of forensic toxicological results. NSW Bureau of crime statistics and research. 40th Anniversary Symposium. Sydney, Australia, 18-19 February 2009.
  • Cytochrome P450 and antidepressant medications. ComBio Conference .The Australian Society for Biochemistry and Molecular Biology. Sydney, Australia, September 22-26, 2007.
  • Application of DHPLC in Molecular Biology. AACB Chromatography and Mass Spectrometry Meeting. Oral Presentation. Sydney, Australia, June 16-18, 2007.
  • Individualized Therapy for Diverse Australian Population. ‘Biology Prospective’ International Conference, Santorini, Greece, September 2006.
  • Efficient screening method for at-risk patients on the thiopurine therapy. International Molecular Medicine Tri-conference, San Francisco, USA, May 2005.
  • HPLC method of Arecoline determination in human saliva. HPLC2003. Nice., France, 2003.
  • Quantitative analysis of gene expression by ion-pair high-performance liquid chromatography during Vitamin D supplementation. HPLC2003, Nice, France, 2003.
  • Metanephrine and Normetanephrine determination by minor modification of standard Catecholamine methodology. XIVth Scientific Research Meeting. Sydney, RNSH, Australia, November 199.
  • Dynamics of the chemical nature of the cell wall of Trichoderma reesei. Fifth International Mycological Congress, Vancouver, Canada, August 1994.

ORGANISED WORKSHOPS

  • NSW Institute of Psychiatry & Transcultural Mental Health Centre. Cross-cultural Mental Health Care in General Practice Workshops, Ethnopsychopharmacogenetics and Personalised Medicine, organised yearly, 2007 -2011.
  • The Mental Health Network Conference Workshop: Individual reactions to antipsychotic and antidepressant drugs. A guide to psychiatric drug interaction. September, 2010.
  • Personalised Medicine. Diversity Health Institute Conference, 2008.

STUDENT SUPERVISION. CURRENT PROJECTS

  • Identification of miRNA profile which characterise T2DM. UWS Honours program.
  • Epigenetics and Type 2 Diabetes. Glucose transporter gene methylation status in Type 2 Diabetes. UWS Honours program.
  • A General Medical Practitioner’s Approach to drug-food interaction in the Culturally and Linguistically Diverse (CALD) community of the Greater Western Sydney (GWS) area. UWS Community Research Project. Student group: year 4 UWS medical students.
  • GP Use of Psychotropic Medication for the Management of Depression in Culturally and Linguistically Diverse ( CALD) community. Community Research Project. Student group: year 4 UWS medical students.
  • General Medical Practitioners appraisal of prescribed psychotropic medications in the context of enzyme polymorphisms in the Blacktown City Council African Community. Community Research Project. Student group: year 4 UWS medical students.

CURRENT PROJECTS

  • Clozapine adverse drug reactions.
  • miRNAs and Type 2 Diabetes.
  • Genetic predisposition to Serotonin Syndrome.
  • Clozapine-induced metabolic diseases and Pharmacogenetics.
  • Evaluation of Fingernail Evidence Collection Procedures commonly used in forensic practice by DNA based methods. (Initiation phase).
  • Variations in the GLUT1(SLC2A1) gene coding area and phenotype-genotype characteristics.
  • Glucose Transporter 1 functional assay development.
  • DNA methylation and metabolic syndrome.

COMPLETED PROJECTS

  • Oxidative DNA Damage Levels in IBD patients Undergoing Infliximab Therapy.
  • Normal thiopurine methyltransferase phenotype testing in a crohn disease patient with azathioprine induced myelosuppression.
  • Venlafaxine Neurotoxic Adverse Drug Reaction and Pharmacogenetics.